1-{4-[2-(4-bromophenyl)-1,3-dioxolan-2-yl]piperidin-1-yl}-2,2,2-trifluoroethanone | 203187-77-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-{4-[2-(4-bromophenyl)-1,3-dioxolan-2-yl]piperidin-1-yl}-2,2,2-trifluoroethanone
• 英文别名: 4-[2-(4-bromophenyl)-1,3-dioxolan-2-yl]-1-trifluoroacetyl-piperidine；4-[2-(4-bromophenyl)-1,3-dioxolan-2-yl]-1-trifluoroacetylpiperidine；1-[4-[2-(4-Bromophenyl)-1,3-dioxolan-2-yl]piperidin-1-yl]-2,2,2-trifluoroethanone
• CAS: 203187-77-3
• 化学式: C₁₆H₁₇BrF₃NO₃
• 分子量: 408.215
• InChiKey: BHWWHWGLYRBFLK-UHFFFAOYSA-N

物化性质

• 沸点：
  482.5±45.0 °C(Predicted)
• 密度：
  1.520±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-{4-[2-(4-bromophenyl)-1,3-dioxolan-2-yl]piperidin-1-yl}-2,2,2-trifluoroethanone 在 titanium(IV) isopropylate 、 盐酸 、 sodium tetrahydroborate 、 甲基溴化镁 、 potassium carbonate 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 、 乙酸乙酯 、 1,2-二氯乙烷 为溶剂， 反应 54.0h， 生成 [4-[4-[(4-Bromophenyl)-hydroxy-methyl]-1-piperidyl]-4-methyl-1-piperidyl]-(2,6-dimethylphenyl)methanone
  参考文献：
  名称：

  Synthesis, SAR, and Biological Evaluation of Oximino-Piperidino-Piperidine Amides. 1. Orally Bioavailable CCR5 Receptor Antagonists with Potent Anti-HIV Activity

  摘要：

  We previously reported the discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1'-[(2,4-dimethyl-3-pyridinyl)carbonyl] -4'-methyl-1,4'-bipiperidine N-oxide 1 (SCH 351125) as an orally bioavailable human CCR5 antagonist for the treatment of HIV-1 infection. Herein, we describe in detail the discovery of 1 from our initial lead compound as well as the synthesis and SAR studies directed toward optimization of substitution at the phenyl, oxime, and right-hand side amide groups in the oximino-piperidino-piperidine series. Substitutions (4-Br, 4-CF3, 4-OCF3, 4-SO2Me, and 4-Cl) at the phenyl group are well-tolerated, and small alkyl substitutions (Me, Et, Pr-n, Pr-i, and cyclopropyl methyl) at the oxime moiety are preferred for CCR5 antagonism. The 2,6-dimethylnicotinamide N-oxide moiety is the optimal choice for the right-hand side. Several compounds in this series, including compound 1, exhibited excellent antiviral activity in vitro. Compound 1, which has a favorable pharmacokinetic profile in rodents and primates, excellent oral bioavailability, and potent antiviral activity against a wide range of primary HIV-1 isolates, is a potentially promising new candidate for treatment of HIV-1 infection.

  DOI：

  10.1021/jm0200815
• 作为产物：
  描述：

  1-(2,2,2-trifluoroacetyl)piperidine-4-carbonyl chloride 在 三氯化铝 、 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 4.0h， 生成 1-{4-[2-(4-bromophenyl)-1,3-dioxolan-2-yl]piperidin-1-yl}-2,2,2-trifluoroethanone
  参考文献：
  名称：

  Discovery of 4-[(Z)-(4-Bromophenyl)- (ethoxyimino)methyl]-1‘-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4‘-methyl-1,4‘- bipiperidine N-Oxide (SCH 351125):  An Orally Bioavailable Human CCR5 Antagonist for the Treatment of HIV Infection

  摘要：

  Structure-activity studies on piperidino-piperidine 3 led to the discovery of SCH 351125 (1), a selective CCR5 antagonist with potent activity against RANTES binding (K-i = 2 nM), which possesses subnanomolar activity in blocking viral entry and has excellent antiviral potency versus a panel of primary HIV-1 viral isolates. Compound 1, which has good oral bioavailability in rats, dogs, and monkeys, is proposed as a potential therapeutic agent for the treatment of HIV-1 and has entered human clinical trials.

  DOI：

  10.1021/jm015526o

文献信息

• [EN] SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 4-BENZYL ET 4-BENZOYL-PIPÉRIDINE SUBSTITUÉS
  申请人：CEPHALON INC

  公开号：WO2016205590A1

  公开（公告）日：2016-12-22

  Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds. Also described herein are methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

  本文描述了根据公式I的1,4-取代哌啶化合物，这些化合物已经表现出作为脂肪酸合酶抑制剂的活性。本文还描述了含有所述1,4-取代哌啶化合物的药物组合物。本文还描述了通过给予本文描述的一个或多个化合物或药物配方治疗由脂肪酸合酶介导的疾病的方法。本文还描述了合成所述1,4-取代哌啶化合物以及在这些合成中有用的合成中间体的方法。
• Substituted 4-benzyl and 4-benzoyl piperidine derivatives
  申请人：89BIO LTD

  公开号：US10919875B2

  公开（公告）日：2021-02-16

  Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds. Also described herein are methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

  本文所述的 1,4-取代的哌啶化合物符合式 I，具有脂肪酸合成酶抑制剂的活性。本文还描述了含有所述 1,4-取代哌啶化合物的药物组合物。本文还描述了通过施用一种或多种本文所述化合物或药物制剂来治疗由脂肪酸合成酶介导的疾病的方法。本文还描述了合成所述 1,4-取代的哌啶化合物和用于这些合成的合成中间体的方法。
• PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS
  申请人：SCHERING CORPORATION

  公开号：EP1175402B1

  公开（公告）日：2005-07-20
• Discovery of 4-[(<i>Z</i>)-(4-Bromophenyl)- (ethoxyimino)methyl]-1‘-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4‘-methyl-1,4‘- bipiperidine <i>N</i>-Oxide (SCH 351125):  An Orally Bioavailable Human CCR5 Antagonist for the Treatment of HIV Infection
  作者：Anandan Palani、Sherry Shapiro、John W. Clader、William J. Greenlee、Kathleen Cox、Julie Strizki、Michael Endres、Bahige M. Baroudy

  DOI：10.1021/jm015526o

  日期：2001.10.1

  Structure-activity studies on piperidino-piperidine 3 led to the discovery of SCH 351125 (1), a selective CCR5 antagonist with potent activity against RANTES binding (K-i = 2 nM), which possesses subnanomolar activity in blocking viral entry and has excellent antiviral potency versus a panel of primary HIV-1 viral isolates. Compound 1, which has good oral bioavailability in rats, dogs, and monkeys, is proposed as a potential therapeutic agent for the treatment of HIV-1 and has entered human clinical trials.
• SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES
  申请人：Cephalon, Inc.

  公开号：EP3310773A1

  公开（公告）日：2018-04-25